Alnylam's Rebound Test: Legal Scrutiny Meets a Deeply Oversold Chart
Published on 08/06/2026 at 02:20 | Redaktion boerse-global.de
The numbers tell a story of resilience, yet the trust deficit lingers. Alnylam Pharmaceuticals shares have clawed back some ground this week, but the damage from late July's guidance cut — and the legal fallout now gathering around it — continues to shape the narrative for investors weighing whether the worst has passed.
At the center of the storm sits a 28.4% single-day collapse on July 30, triggered when the company trimmed its full-year 2026 revenue outlook for its TTR franchise. The revised range for TTR net product sales now sits at $4.2 billion to $4.5 billion, down from a prior $4.4 billion to $4.7 billion — a $200 million reduction at the lower end. Management attributed the move to a "normalization" of demand for Amvuttra in the ATTR-CM market following the initial launch phase.
Three Law Firms, One Question
That same day, the legal machinery began to turn. Schall, Brown & Schwartz LLP opened an investigation into potential securities law violations tied to the guidance revision, joining Glancy Prongay Wolke & Rotter LLP and Bragar Eagel & Squire, P.C., which had launched their own probes a day earlier. The firms are examining whether Alnylam's prior communications misled investors about the growth trajectory of its TTR business and the durability of its 2026 outlook.
Such investigations are almost routine after moves of this magnitude, but they add a layer of overhang that typically slows any recovery. The credibility question now extends beyond the numbers themselves — it's about whether management can rebuild confidence after having to walk back its own projections.
Should investors sell immediately? Or is it worth buying Alnylam?
The Chart Suggests Exhaustion
Despite the legal noise, technical signals point to a market that has largely priced in the bad news. Shares traded at €197.60 on Wednesday, up 4.41% on the day and following a 4.2% gain the previous session, when the stock closed at €189.25. That places the equity roughly 14.55% above its recent 52-week low of €172.15 — early evidence that a floor may be forming.
The 14-day relative strength index stands at 35.2, deep in oversold territory. Historically, that's the zone where buyers tend to step back in, and it suggests the most aggressive sellers have already exited their positions.
Still, the recovery attempt does little to mask the broader damage. The stock remains roughly half its 52-week high of €425.00, reached on October 21, and has shed 41.81% since the start of the year.
A Valuation Gap That's Hard to Ignore
For those inclined to look past the near-term turbulence, the valuation argument carries weight. The average analyst price target stands at €334.45, implying upside of 69.6% from current levels. Even incorporating the reduced TTR guidance, a market capitalization of €23.86 billion looks thin for a company with Alnylam's position in the oligonucleotide therapeutics space — a sector projected to approach $11 billion by 2030, growing at 12% annually.
The second-quarter results themselves offered a mixed picture. Total revenue of $1.291 billion came in below the consensus estimate of $1.323 billion, but adjusted earnings per share of $1.84 blew past expectations of $1.55. TTR net product sales reached $1.03 billion, up 89% year over year — growth that seems at odds with the market's reaction, yet failed to assuage concerns about a coming slowdown.
Analyst Divergence and Competitive Tailwinds
Wall Street's response has been far from uniform. Raymond James upgraded the stock from "Outperform" to "Strong Buy" on August 3, setting a price target of $420.00 and citing an attractive risk-reward profile following the sell-off. That same day, RBC Capital lowered its target from $445.00 to $350.00 while maintaining an "Outperform" rating. The broader pattern among other firms: reduced targets, but largely positive-to-neutral stances.
Alnylam at a turning point? This analysis reveals what investors need to know now.
Meanwhile, Alnylam has been busy on the strategic front. The company signed an exclusive agreement with BeOne Medicines to commercialize Amvuttra (vutrisiran) in China, launched a collaboration with Inceptive to integrate artificial intelligence into its RNAi platform, and partnered with a California health system to improve early ATTR-CM diagnosis. It also reaffirmed its commitment to the Phase 3 TRITON-CM study of Nucresiran (ALN-TTRsc04) in ATTR-CM.
Unexpected support came from the competition: AstraZeneca and Ionis Pharmaceuticals reported that their Phase 3 CARDIO-TTRansform trial of Eplontersen in ATTR-CM missed its primary efficacy endpoint — news that should ease competitive pressure on Amvuttra, even if it doesn't resolve the immediate credibility crisis.
A Stock for Steady Hands
The path forward is anything but smooth. Management must first rebuild trust after the guidance reversal, and the legal investigations will likely cast a shadow over the coming months. But with the stock trading at a more than 50% discount to its own annual high and volatility running above 95% on an annualized basis, this remains a name for investors with strong stomachs. If Alnylam can demonstrate operational stability in the quarters ahead, the gap to that €334.45 price target could begin to close. Until then, the market's verdict on this stock is still being written — one legal filing and one earnings report at a time.
Ad
Alnylam Stock: New Analysis - 6 August
Fresh Alnylam information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
